Navigation Links
Study to examine new treatment for West Nile virus
Date:8/18/2010

(CHICAGO) Neurological and infectious disease experts at Rush University Medical Center are testing a new drug therapy for the treatment of individuals with West Nile fever or suspected central nervous system infection due to the West Nile virus. Rush is the only site in the Midwest enrolling patients into the $50 million dollar, NIH-funded, Phase II clinical trial called PARADIGM.

The new drug treatment for West Nile virus that is being tested, also known as MGAWN1, is a humanized monoclonal antibody, which is a drug engineered to help the body seek and destroy the virus. During the randomized, double-blind study, patients with the signs and symptoms of West Nile virus will receive either a single infusion of MGAWN1 or a placebo.

"Currently, there are no approved treatments for people with severe West Nile virus infection and there is no standard of care that is highly effective against it," said Dr. Russell Bartt, neurologist and lead site investigator of the study at Rush. "Patients with the disease are hospitalized and receive supportive care."

"This new drug therapy has the potential of neutralizing the virus and could possibly reduce or prevent complications associated with the West Nile neuroinvasive disease," said Bartt. "This could represent a significant advancement for patients with West Nile."

The monoclonal antibody latches on to the West Nile virus in order for the body's immune system to recognize and eliminate it. The treatment will hopefully reduce the severity and also shorten the length of the disease.

The PARADIGM study will be testing the safety and tolerability of the drug therapy in infected patients. The first phase of the study of MGAWN1 tested doses in healthy adults and demonstrated adequate safety and was tolerated well.

West Nile virus is a disease transmitted through the bite of an infected mosquito. When someone is bitten by an infected mosquito, the virus can enter the blood stream and circulate. . The virus may be eliminated, but in some cases, it may end up in the tissues in the body, lymph nodes, as well as invade neurological tissues where the virus replicates and may cause symptoms in days and weeks.

Since 1999, there have been more than 29,000 cases of confirmed West Nile virus infection in the U.S. About 20 percent of humans infected with the West Nile virus experience West Nile fever with symptoms that include fever, headache, body aches, stiff neck, muscle weakness, confusion, skin rash, and swollen lymph glands.

In about one percent of human infections, West Nile virus enters the brain and spinal cord causing severe, life-threatening neuroinvasive disease. In these types of serious cases, West Nile virus can cause encephalitis (inflammation of the brain), meningitis (inflammation of the coverings in the brain and spinal cord), or acute flaccid paralysis.


'/>"/>

Contact: Deb Song
deb_song@rush.edu
312-942-0588
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. When Doctors Admit Mistakes, Fewer Malpractice Suits Result, Study Says
2. MRSA policies differ among hospitals, study shows
3. Study examines risks, rewards of energy drinks
4. Berkeley study shows ozone and nicotine a bad combination for asthma
5. Henry Ford Hospital study: Donor Risk Index does not impact outcomes on a small scale
6. In NIH-funded study, researchers uncover step in brain events leading up to addiction
7. Lithium of No Benefit in ALS, Study Finds
8. Study shows behaviors and attitudes towards oral sex are changing
9. Study Offers Support for Surgery After Compression Fracture
10. More Medicaid Patients Using ERs, Study Finds
11. Study shows physicians reluctant to use chemoprevention for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... ANGELES (PRWEB) , ... October 12, 2017 , ... ... Parsa Mohebi Hair Restoration, has recently contributed a medical article to the newly ... on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: